Cyclacel Pharmaceuticals Inc [NASDAQ: CYCC] traded at a high on 2025-07-15, posting a 272.51 gain after which it closed the day’ session at $12.33.
The results of the trading session contributed to over 63067572 shares changing hands. Over the past one week, the price volatility of Cyclacel Pharmaceuticals Inc stands at 78.30% while the volatility over the past one month is 31.71%.
The market cap for CYCC stock reached $19.52 million, with 1.58 million shares outstanding and 1.58 million shares in the current float. Compared to the average trading volume of 210.26K shares, CYCC reached a trading volume of 63067572 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Cyclacel Pharmaceuticals Inc [CYCC]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CYCC shares is $240.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CYCC stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Oppenheimer have made an estimate for Cyclacel Pharmaceuticals Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on July 18, 2022. While these analysts kept the previous recommendation, ROTH Capital raised their target price to Buy. The new note on the price target was released on April 27, 2020, representing the official price target for Cyclacel Pharmaceuticals Inc stock.
The Price to Book ratio for the last quarter was 3.48, with the Price to Cash per share for the same quarter was set at 2.18.
How has CYCC stock performed recently?
Cyclacel Pharmaceuticals Inc [CYCC] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 266.96. With this latest performance, CYCC shares gained by 128.97% in over the last four-week period, additionally sinking by -87.76% over the last 6 months – not to mention a drop of -86.34% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CYCC stock in for the last two-week period is set at 57.15, with the RSI for the last a single of trading hit 2.69, and the three-weeks RSI is set at 3.58 for Cyclacel Pharmaceuticals Inc [CYCC]. The present Moving Average for the last 50 days of trading for this stock 21.02, while it was recorded at 5.46 for the last single week of trading, and 85.14 for the last 200 days.
Cyclacel Pharmaceuticals Inc [CYCC]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Cyclacel Pharmaceuticals Inc [CYCC] shares currently have an operating margin of -96235.71% and a Gross Margin at 71.43%. Cyclacel Pharmaceuticals Inc’s Net Margin is presently recorded at -59607.14%.
Return on Equity for this stock declined to -168.60%, with Return on Assets sitting at -168.60%.
Insider trade positions for Cyclacel Pharmaceuticals Inc [CYCC]
There are presently around $6.64%, or 17.24% of CYCC stock, in the hands of institutional investors.
